Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Under-the-Tongue vaccine shows promise for COPD patients

NCT ID NCT01842360

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 29 times

Summary

This study tested a bacterial vaccine spray (MV130) taken daily under the tongue for 12 months in 198 adults with moderate to severe COPD. The goal was to see if it could reduce the number and severity of lung flare-ups compared to a placebo. Researchers also monitored safety and quality of life during the 18-month study period.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Hospital Clínico San Carlos

    Madrid, 28040, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, 28007, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Infanta Leonor

    Madrid, 28031, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital Universitario de Torrejón

    Torrejón de Ardoz, Madrid, 28850, Spain

  • Hospital Universitario de Vic

    Vic, Barcelona, 08500, Spain

Conditions

Explore the condition pages connected to this study.